<DOC>
	<DOCNO>NCT02229084</DOCNO>
	<brief_summary>The purpose study evaluate investigational agent , P10s-PADRE , peptide mimotope-based vaccine , combination standard neoadjuvant chemotherapy patient clinical stage I , II III estrogen-receptor ( ER ) -positive breast cancer . This single-arm , multi-site Phase I/II study design two goal ( 1 ) evaluate feasibility combine vaccination P10s-PADRE formulation neoadjuvant chemotherapy ( 2 ) determine pCR rate among ER-positive breast-cancer patient treat combination significantly high 8 % rate observe among ER-positive breast-cancer subject pool analysis seven randomize clinical trial . P10s-PADRE vaccine MONTANIDE™ ISA 51 VG adjuvant give combination neoadjuvant chemotherapy female patient clinical stage I , II III ER-positive breast cancer .</brief_summary>
	<brief_title>Vaccination High Risk Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Females race clinical stage I , II , III ERpositive breast cancer qualify standard neoadjuvant treatment Age 18 year old ECOG Performance Status 0 1 . White blood cell ( WBC ) count ≥ 3,000/mm3 within 2 week prior registration . Platelet count ≥ 100,000/mm3 within 2 week prior registration . Serum glutamicoxaloacetic transaminase ( SGOT ) ≤ 2 x institutional upper limit ( IUL ) normal obtain within 2 week prior registration . Aspartate aminotransferase test ( AST ) ≤ 2 x institutional upper limit ( IUL ) normal obtain within 2 week prior registration . Bilirubin ≤ 2 x institutional upper limit ( IUL ) normal obtain within 2 week prior registration . Serum creatinine ≤ 1.8 mg/dl obtain within 2 week prior registration . Must sign inform consent approve UAMS Institutional Review Board ( IRB ) . Active infection require treatment antibiotic . Diagnosis evidence organic brain syndrome might preclude participation full protocol . Diagnosis evidence significant impairment basal cognitive function might preclude participation full protocol . No current malignancy . Subjects prior history time situ cancer , include lobular carcinoma breast situ , cervical cancer situ , atypical melanocytic hyperplasia Clark I melanoma situ basal squamous skin cancer eligible , provide diseasefree time registration . Subjects malignancy eligible continuously disease free ≥ 5 year prior time registration . Autoimmune disorder condition immunosuppression . This include , limited treat corticosteroid , include oral steroid ( i.e . prednisone , dexamethasone [ except use antiemetic standard therapy ] ) , continuous use topical steroid cream ointment steroidcontaining inhaler . Subjects discontinue use class medication least 6 week prior registration eligible , judgment treat physician , subject likely require class drug treatment period . Replacement dose steroid subject adrenal insufficiency allow . Pregnancy breast feeding ( due unknown effect peptide/mimotope vaccine fetus infant ) . Women childbearing potential must negative urine pregnancy test within 72 hour prior receive first dose study drug must counsel use accepted effective method contraception ( include abstinence ) treatment period 18 month complete discontinue treatment . Accepted method contraception include oral contraceptive , barrier method , IUDs , abstinence . Any significant medical psychiatric condition , opinion enrol investigator , may interfere consent compliance treatment regimen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>